Saturday, November 21, 2026
Maricel Sequeira
- Costa Rica, taking the 1992 International Biodiversity Convention seriously, has begun identifying its flora and fauna and working on strategies for rational exploitation.
The nation is extremely rich in biodiversity, possessing some five percent of the world total.
The identification of biogenetic resources in the 10,000 hectares of dry tropical forest in Northern Costa Rica started in March, supported by a 12 million dollar contribution from the Dutch government. The area holds 60 percent of the 500,000 animal and vegetable species within Costa Rican territory.
The first project will last two years, but a further 100 million dollars will be sought for a further seven-year effort to identify all of the Costa Rican genetic resources.
Minister of Environment and Energy, Rene Castro, said the government would put the results of the project on the Internet, to avoid duplication of effort in the international community.
At the same time, Costa Rica is working on the domestication of species like Lonchocarpus – known locally as the ‘chaperno tree’ – which many institutions think could answer their dreams of producing an organic nematocide. If this were possible, it would advance the war on nematodes – the small hard-skinned worms that cause considerabkle damage to crops.
This tree, grows naturally in the dry tropical forest, and the British Technology Group (BTG) extracted from it, and patented, an anti-nematode compound known as DMDP.
The National Biodiversity Institute (Inbio), a non-governmental organisation (NGO), negotiated with the BTG to provide it with chaperno seeds in return for 30 percent of the profits going to the National Parks Fund. During the experimentation phase, trials of DMDP were run on the banana plantations.
Castro pointed out that the synthetic nematocides are very expensive and extremely toxic, therefore having a high environmental price.
At present it costs around 6,000 dollars per hectare per year to maintain a plantation free of the pest – Costa Rica has 40,000 hectares of banana plantations and this means total expenditure of 240 million dollars a year on the poisons.
The chaperno-based product could also be used in coffee, sugar, oil palms, melon, tomato and potato.
Castro warned that the investigation still presented a high risk, because the production costs have yet to be determined, and the product may be easily leached by rainwater and therefore of little use. It could also be damaging to other life forms, including human beings, in which case it would have to be abandonned.
Nicolas Mateo, coordinator of the Inbio Prospector Division, said that in two years’ time it would be possible to have a clear idea of its viability.
Mateo said that the fact this investigation was being carried out in Costa Rica, and that the nation stood to benefit from the outcome, signified a change in North-South biodiversity relations as a result of the Biodiversity Treaty.
Before 1992, “biodiversity was human heritage and as such, anybody could take tropical species with no problem. But that year the rules changed,” he explained. It was under the ‘human heritage’ clause that BTG first took the chaperno samples out of the country, ran preliminary studies, extracted the DMDP and patented it.
If the chaperno nematocide does ‘come up trumps,’ Costa Rica will negotiate the royalties due the country for being the source of the genes used, Mateo said..
This negotiation would not have been possible before the approval of the International Convention, when any business could patent a product or exploit it irrespective of where the genes came from, he added.
However, the Convention recognised that the biodiversity of a nation was its property and Inbio has signed several agreements with pharmaceutical transnationals and other research centres.
The pact for the investigation of the species with Merck Sharp and Dohme has already given Inbio a million dollars every two years since 1992, along with technology transfer, laboratory equipment and staff training. This transnational must pay royalties to Costa Rica for any medicines based on the nation’s species that it manages to market.
Developing these is no easy matter and Mateo said that of 10,000 substances analysed, only one has possibilities of being used in the pharmaceutical industry.
The research will last between 10 and 15 years and the average cost of launching a new drug on the market is between 300 and 400 million dollars.
As far as the chaperno nematocide is concerned, this could mean a massive payout for Costa Rica – a nation which 30 years ago decided to protect its natural resources in a system of national parks which currently cover more than a fifth of the country.